Arvid Carlsson

Arvid Carlsson was born on January 25, 1923, in Uppsala, Sweden. Carlsson grew up in Sweden and pursued a career in medicine and pharmacology. He made a significant impact on neuroscience and pharmacology, most notably for his work on neurotransmitters.

In 1972, Arvid Carlsson was appointed as a full professor of pharmacology at the University of Gothenburg. This position allowed him to further his research on neurotransmitters like dopamine and expand his influence in the field of neuroscience and pharmacology.

In 2010, Arvid Carlsson was honored with the Grand Cross of the Order of Civil Merit by the King of Spain, recognizing his significant contributions to science, particularly in the field of neuroscience and pharmacology, and his impact on understanding and treating neurological disorders.

In 2002, Arvid Carlsson founded Carlsson Research AB, a pharmaceutical company aimed at developing new treatments for neurological and psychiatric disorders. This venture was part of his ongoing commitment to improving drug therapies in neuroscience, leveraging his expertise to address unmet medical needs.

After an illustrious career, Arvid Carlsson retired from his official position at the University of Gothenburg in 1990. However, he continued to be active in research and the scientific community, contributing his knowledge and experience to ongoing projects and initiatives.

In 1944, Arvid Carlsson completed his Bachelor of Medicine at Lund University. This was a significant step in his journey to becoming a renowned pharmacologist and neuroscientist. His studies laid the groundwork for his future research in medical sciences.

In 1957, Arvid Carlsson discovered that dopamine is not just a precursor of norepinephrine and epinephrine but also a neurotransmitter in its own right. This was a groundbreaking discovery as it established the role of dopamine in brain function, affecting motor control and reward systems and leading to a better understanding of Parkinson's disease.

In October 2000, Arvid Carlsson was awarded the Nobel Prize in Physiology or Medicine, together with Paul Greengard and Eric Kandel, for their discoveries concerning signal transduction in the nervous system. Carlsson's research on dopamine led to an improved understanding of the pathophysiology and treatment of neurological and psychiatric disorders like Parkinson's disease.

Arvid Carlsson passed away on June 29, 2018, at the age of 95. His contributions to the field of neuroscience and pharmacology, particularly his work on dopamine as a neurotransmitter, have left a lasting legacy in the scientific community. Carlsson's work has had significant implications for the understanding and treatment of neurological diseases.